Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Fudan University
Fujian Cancer Hospital
RemeGen Co., Ltd.
Ludwig-Maximilians - University of Munich
Shanghai JMT-Bio Inc.
Hospital Israelita Albert Einstein
Changhai Hospital
Criterium, Inc.
Biocity Biopharmaceutics Co., Ltd.
Nanfang Hospital, Southern Medical University
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Second Affiliated Hospital, School of Medicine, Zhejiang University
Salah Azaïz Cancer Institute
Fujian Cancer Hospital
National Cancer Center, Korea
Fudan University
Zhejiang Cancer Hospital
Fujian Medical University
Fujian Cancer Hospital
Akeso
Zhejiang Cancer Hospital
Zhejiang Cancer Hospital
Australasian Gastro-Intestinal Trials Group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
The First Affiliated Hospital of Zhengzhou University
Khon Kaen University
Jiangsu Cancer Institute & Hospital
West China Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Sixth Affiliated Hospital, Sun Yat-sen University
Grupo Espanol Multidisciplinario del Cancer Digestivo
Nanfang Hospital, Southern Medical University
China Medical University, China
China Medical University, China
China Medical University, China
Blokhin's Russian Cancer Research Center
Blokhin's Russian Cancer Research Center
Fudan University
Fudan University
Assiut University
Guangdong Association of Clinical Trials
Taizhou Hanzhong biomedical co. LTD
Shanghai JMT-Bio Inc.
Benaroya Research Institute
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sixth Affiliated Hospital, Sun Yat-sen University
Fudan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Peking Union Medical College Hospital